Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.45 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2004934 | 1.00 | SLC18A3 (0.45) | SLC18A3PHGDHMGLLMEN1KMT2A | |
| SCHEMBL6378958 | 1.00 | SLC18A3 (0.45) | SLC18A3PHGDHMGLLMEN1KMT2A | |
| SCHEMBL736256 | 0.97 | SLC18A3 (0.42) | SLC18A3PHGDHMGLLMEN1KMT2A | |
| SCHEMBL2011528 | 0.93 | SLC18A3 (0.41) | SLC18A3PHGDHMGLLMEN1KMT2A | |
| SCHEMBL2011143 | 0.93 | SLC18A3 (0.41) | SLC18A3PHGDHMGLLMEN1KMT2A | |
| SCHEMBL735809 | 0.92 | L3MBTL3 (0.38) | SLC18A3PHGDHMGLLMEN1KMT2A | |
| SCHEMBL2006298 | 0.91 | L3MBTL3 (0.41) | SLC18A3PHGDHMGLLMEN1KMT2A | |
| SCHEMBL2003309 | 0.91 | L3MBTL3 (0.41) | SLC18A3PHGDHMGLLMEN1KMT2A | |
| SCHEMBL2009840 | 0.90 | L3MBTL3 (0.39) | SLC18A3PHGDHMGLLMEN1KMT2A | |
| SCHEMBL2003194 | 0.88 | L3MBTL3 (0.42) | SLC18A3MEN1KMT2AL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077387-B1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-20 | — | — | EP | claimed |
| US-9562035-B2 | Benzamide derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-07 | — | — | US | claimed |
| EP-3077387-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica, N.V. (BE) | 2016-10-12 | — | — | EP | claimed |
| US-20160009688-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | claimed |
| WO-2015084606-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-11 | — | — | WO | claimed |
| CN-103347385-A | Diazeniumdiolate heterocyclic derivatives | MERCK SHARP & DOHME | 2013-10-09 | — | — | CN | claimed |
| CN-102153544-A | Preparation method and application of novel tyrosine kinase inhibitors | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2011-08-17 | — | — | CN | claimed |
| EP-1140839-B1 | HETEROCYCLIC AMIDES AS INHIBITORS OF FACTOR XA | LILLY CO ELI (US) | 2004-03-17 | — | — | EP | claimed |
| US-6660739-B1 | Heterocyclic amides as inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-12-09 | — | — | US | claimed |
| EP-1140839-A1 | HETEROCYCLIC AMIDES AS INHIBITORS OF FACTOR XA | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000039092-A1 | HETEROCYCLIC AMIDES AS INHIBITORS OF FACTOR Xa | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | claimed |
| CN-110997678-B | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-02-21 | — | — | CN | disclosed |
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| CN-110997678-A | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2020-04-10 | — | — | CN | disclosed |
| EP-1140839-A1 | HETEROCYCLIC AMIDES AS INHIBITORS OF FACTOR XA | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039092-A1 | HETEROCYCLIC AMIDES AS INHIBITORS OF FACTOR Xa | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-0625507-B1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | SLC18A3 14/4885PHGDH 1354/4885MGLL 2720/4885 |
| US-20160009688-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, FABP1, BCL3 | SLC18A3 4771/4885PHGDH 1228/4885MGLL 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.